CTOs on the Move

Intelligent Medical Objects

www.e-imo.com

 
Intelligent Medical Objects® (IMO®) is the market leader in clinical interface terminology and a strategic partner with major content providers and EHR developers. IMO delivers a comprehensive suite of integrated, clinician-friendly medical vocabulary solutions that enable healthcare organizations to improve patient documentation, streamline workflow, coordinate care and increase revenue. IMO`s leading Clinical Interface Terminology products, including IMO® Problem (IT)™ and IMO® Procedure (IT)™, provide seamless mapping of diagnostic terminologies to billing codes and medical concepts, enhancing decision support, research, patient education, and financial operations. IMO provides the tools necessary for healthcare organizations to authoritatively support uniform labeling of health profiles, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.e-imo.com
  • 60 Revere Dr
    Northbrook, IL USA 60062
  • Phone: 847.272.1242

Executives

Name Title Contact Details

Similar Companies

Universal Media

Universal Media is a Mechanicsburg, PA-based company in the Business Services sector.

CyberArts Licensing

CyberArts Licensing is a San Francisco, CA-based company in the Business Services sector.

CandL Marketing

C&L Marketing is a Glen Cove, NY-based company in the Business Services sector.

Forbes Mergers and Acquisitions

Forbes Mergers and Acquisitions is a Englewood, CO-based company in the Business Services sector.

Vansen Pharma, Inc.

Vansen Pharma Inc. is a specialty pharmaceutical company focused on broad therapeutic areas that are anticipated to grow and present an opportunity for major expansion.  Vansen will expand its commercial presence by adding complimentary products through in-licensing, co-promotion and acquisitions, resulting in a comprehensive product portfolio.  With its US based sales force, Vansen can better serve the increasing healthcare needs of patients and enhance growth.  Vansen's current product portfolio of anti-infectives, including Factive®, Spectracef® and Cefditoren Pivoxil®, provides a strong and stable revenue base from which to grow and expand our company. Our experienced management team is aggressively pursuing acquisitions of accretive specialty products, including legacy drugs and cash flow positive healthcare companies.  We look forward to executing our growth strategy and creating lasting shareholder value for our investors.